Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Suspended × Lymphoma, B-Cell, Marginal Zone × deltacortene × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lymphoma 1 HTLV-I Infections 1

Interventions

prednylidene 1 deltacortene 1 cc-486 1 Vincristine 1 Specimen Handling 1 Rituximab 1 Prednisone 1 Doxorubicin 1 Cyclophosphamide 1 CT-P10 1 Azacitidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04799275 2026-03-19

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Suspended

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon ⚡